
A large-scale prospective study involving 30,013 pregnancies examined the effectiveness of placental growth factor (PlGF) testing at 19–23 weeks of gestation in predicting adverse outcomes. The study, conducted across two English maternity units, revealed that while clinical risk factors identified 41.7%–54.7% of adverse outcomes, they couldn't significantly revise the risk. Low PlGF levels detected 8.5%–17.4% of adverse outcomes, mainly increasing risks associated with preterm delivery. Combining clinical factors and PlGF testing (two-stage screening) detected 4.2%–8.9% of adverse outcomes. However, no strategy significantly altered outcome detection at term. The study concludes that PlGF testing alone isn't useful for predicting adverse outcomes.
Like
Save
Share